Aetna modified CPB 0234 covering chelation therapy, effective February 13, 2026. Here's what billing teams need to know before submitting claims.
Aetna, a CVS Health company, updated its chelation therapy coverage policy under CPB 0234 in the Aetna system. This policy governs reimbursement for HCPCS codes J0895 (deferoxamine mesylate), J0600 (edetate calcium disodium), J0470 (dimercaprol), J3520 (edetate disodium), and M0300 (IV chelation therapy), along with CPT codes 83015, 83018, and 83785 for heavy metal testing. If your practice bills for iron overload management, heavy metal toxicity treatment, or related infusion services, this update directly affects your charge capture and clinical documentation requirements.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Chelation Therapy — CPB 0234 |
| Policy Code | CPB 0234 |
| Change Type | Modified |
| Effective Date | February 13, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, Nephrology, Toxicology, Infusion/Oncology, Internal Medicine |
| Key Action | Audit clinical documentation to confirm serum ferritin baselines and lab-confirmed heavy metal toxicity before submitting claims under J0895, J0600, J0470, or M0300 |
Aetna Chelation Therapy Coverage Criteria and Medical Necessity Requirements 2026
Aetna's chelation therapy coverage policy splits into two distinct tracks: deferoxamine mesylate (J0895) and "other chelation therapy" covering agents like dimercaprol (J0470), edetate calcium disodium (J0600), and edetate disodium (J3520). The criteria differ materially between them. Know which track your patient falls under before you submit.
Deferoxamine Mesylate (J0895) — Initial Approval
Aetna considers deferoxamine mesylate medically necessary for three indications only. First, transfusional iron overload in members with chronic anemia — but only when the pretreatment serum ferritin level exceeds 1,000 mcg/L. Second, aluminum toxicity in members actively undergoing dialysis. Third, hereditary hemochromatosis when phlebotomy is not an option due to poor venous access, underlying medical disorders, or an unsatisfactory response to phlebotomy.
The prescriber requirement is not optional. Deferoxamine mesylate must be prescribed by or in consultation with a hematologist or nephrologist. Missing this documentation is a fast path to claim denial.
Deferoxamine Mesylate — Continuation of Therapy
Continuing therapy under J0895 requires documented evidence of benefit. For transfusional iron overload, the member's serum ferritin must show a measurable decrease compared to the pretreatment baseline. For aluminum toxicity, you need either decreased serum aluminum concentrations or documented symptomatic improvement — neurological symptom resolution or decreased bone pain both qualify. For hereditary hemochromatosis, you again need a documented ferritin decline from baseline.
If you can't show objective improvement in the chart, prior authorization renewal will fail. Build the lab comparison into your clinical documentation workflow now.
Other Chelation Therapy — Broader Coverage, Tighter Diagnosis Requirements
For agents beyond deferoxamine mesylate, Aetna's Aetna chelation therapy coverage policy covers 10 specific indications. Heavy metal toxicity — covering arsenic, cadmium, copper, gold, iron, lead, and mercury — is covered, but only when two criteria are both met: the member's symptoms are consistent with heavy metal toxicity, AND lab testing confirms it.
Aetna specifically flags lead toxicity documentation. Whole blood lead level is the required test. Urinary lead level is not an acceptable substitute because it reflects plasma lead concentration, not blood lead — and plasma lead fluctuates too quickly to be reliable. If your lab orders are pulling urinary lead only, that's a documentation problem waiting to become a claim denial.
Heavy Metal Testing — CPT 83015, 83018, and 83785
Aetna covers laboratory testing for heavy metal poisoning under CPT 83015 (heavy metal screen), 83018 (quantitative, each), and 83785 (manganese) — but only for members with specific signs and symptoms of heavy metal toxicity or a documented history of likely exposure. Screening for members with only vague or nonspecific symptoms is not covered. Confirm the clinical justification is in the chart before ordering and billing these codes.
Aetna Chelation Therapy Exclusions and Non-Covered Indications
Aetna considers deferoxamine mesylate experimental, investigational, or unproven for any indication not listed in the three covered categories above. That language matters for your claims. Any use of J0895 outside of transfusional iron overload (with ferritin > 1,000 mcg/L), aluminum toxicity in dialysis patients, or hereditary hemochromatosis without phlebotomy eligibility will be denied.
The non-covered use case that generates the most friction in practice is chelation therapy for cardiovascular indications — sometimes billed under M0300 (IV chelation therapy, chemical endarterectomy). Aetna does not consider this medically necessary. Billing M0300 for prevention of cardiovascular events in diabetes patients, for example, will not pass Aetna's medical necessity review regardless of ICD-10 coding under E08–E13. The policy does list those diabetes diagnosis codes in the ICD-10 table, but they map to the "prevention of diabetes-associated cardiovascular events" category — and chelation for that purpose is not covered.
Sickle cell anemia is covered for chelation therapy generally — but Aetna explicitly excludes sickle-cell ulcers (D57.00–D57.819) from coverage for this indication. Make sure your ICD-10 coding distinguishes the underlying condition from wound complications.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Transfusional iron overload in chronic anemia (ferritin > 1,000 mcg/L) | Covered | J0895 | Prescriber must be or consult hematologist/nephrologist; continuation requires documented ferritin decline |
| Aluminum toxicity in dialysis patients | Covered | J0895 | Continuation requires decreased serum aluminum or documented symptom improvement |
| Hereditary hemochromatosis (phlebotomy not an option) | Covered | J0895 | Must document why phlebotomy is contraindicated or failed |
| Heavy metal toxicity (arsenic, cadmium, copper, gold, iron, lead, mercury) | Covered | J0470, J0600, J3520, M0300 | Requires both symptomatic presentation AND lab confirmation; whole blood lead (not urinary) for lead |
| Aceruloplasminemia | Covered | J0470, J0600, J3520 | — |
| Aluminum overload in end-stage renal failure | Covered | J0895, J0600 | — |
| Biliary cirrhosis | Covered | Other chelation agents | — |
| Cooley's anemia (thalassemia major) | Covered | J0895, J0600, J3520 | ICD-10 D56.x |
| Cystinuria | Covered | Other chelation agents | ICD-10 E72.01 |
| Diamond-Blackfan anemia | Covered | Other chelation agents | ICD-10 D61.01 |
| Secondary hemochromatosis (incl. IPSS Low/Int-1 MDS) | Covered | J0895, J0600 | ICD-10 D46.x applies for MDS |
| Sickle cell anemia | Covered | Other chelation agents | ICD-10 D57.x — excludes sickle-cell ulcers |
| Wilson's disease | Covered | Other chelation agents | ICD-10 E83.01 |
| Heavy metal screening (vague/nonspecific symptoms only) | Not Covered | CPT 83015, 83018, 83785 | Must have specific signs/symptoms or documented exposure history |
| Deferoxamine mesylate for all other indications | Experimental/Investigational | J0895 | Blanket exclusion outside the three listed indications |
| IV chelation for cardiovascular event prevention (diabetes) | Not Covered | M0300 | Not considered medically necessary despite ICD-10 E08–E13 appearing in the code table |
| Chelation for sickle-cell ulcers | Not Covered | — | Excluded even though D57.x is listed |
Aetna Chelation Therapy Billing Guidelines and Action Items 2026
These are direct actions for your billing and clinical documentation teams. The effective date is February 13, 2026 — if you haven't done these yet, do them now.
| # | Action Item |
|---|---|
| 1 | Confirm the prescriber consultation requirement before billing J0895. Every deferoxamine mesylate claim needs documentation that a hematologist or nephrologist either prescribed or was consulted. This applies to initial and continuation claims. Add a checklist field to your prior authorization workflow. |
| 2 | Pull pretreatment serum ferritin levels for every iron overload claim. Aetna's coverage policy for transfusional iron overload under CPB 0234 requires a documented baseline ferritin above 1,000 mcg/L. For continuation claims, the chart must show a ferritin decrease from that baseline. Build this into your lab documentation protocol now — not at the time of the denial. |
| 3 | Switch lead toxicity documentation to whole blood lead testing. If your providers currently order urinary lead levels to confirm lead toxicity before billing heavy metal chelation, that won't satisfy Aetna's criteria. Whole blood lead is the required test. Work with your ordering providers and lab to update the order set. |
| 4 | Audit any M0300 claims for cardiovascular indications. IV chelation therapy billed under M0300 for diabetes-related cardiovascular event prevention is not covered under this policy. If your team has been submitting these claims, review the last 12 months of M0300 billing for Aetna patients and assess your exposure. Talk to your compliance officer before filing adjustments. |
| 5 | Update your charge capture for infusion administration codes. CPT codes 96365–96371 for IV and subcutaneous infusion administration and 96372 for injection are listed as "other CPT codes related to the CPB." Pair these correctly with the drug HCPCS codes (J0895, J0600, J0470, J3520) and confirm your facility or practice billing guidelines reflect the correct infusion time units. |
| 6 | Review ICD-10 code specificity for sickle cell claims. Aetna covers chelation therapy for sickle cell anemia (D57.00–D57.819) but explicitly excludes sickle-cell ulcers. Make sure your coders are selecting the correct ICD-10 code for the underlying hematologic condition — not a wound complication code. |
| 7 | Verify prior authorization requirements with your Aetna rep or provider portal. This coverage policy doesn't explicitly list prior authorization requirements in the summary, but given the complexity of the criteria — especially for continuation therapy — assume Aetna will require PA for ongoing deferoxamine mesylate. If you're unsure how this applies to your patient mix, check with your compliance officer before the effective date for any pending claims. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Chelation Therapy Under CPB 0234
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 83015 | CPT | Heavy metal (e.g., arsenic, barium, beryllium, bismuth, antimony, mercury); screen |
| 83018 | CPT | Quantitative, each |
| 83785 | CPT | Manganese |
Other CPT Codes Related to CPB 0234
These infusion and injection administration codes are used to bill for chelation therapy delivery. Pair them with the appropriate drug HCPCS code.
| Code | Type | Description |
|---|---|---|
| 96365 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug) |
| 96366 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug) |
| 96367 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug) |
| 96368 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug) |
| 96369 | CPT | Subcutaneous infusion for therapy or prophylaxis (specify substance or drug) |
| 96370 | CPT | Subcutaneous infusion for therapy or prophylaxis (specify substance or drug) |
| 96371 | CPT | Subcutaneous infusion for therapy or prophylaxis (specify substance or drug) |
| 96372 | CPT | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular |
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| G0068 | HCPCS | Professional services for the administration of anti-infective, pain management, chelation, pulmonary hypertension, or inotropic infusion drug(s) |
| J0470 | HCPCS | Injection, dimercaprol, per 100 mg |
| J0600 | HCPCS | Injection, edetate calcium disodium, up to 1,000 mg |
| J0895 | HCPCS | Injection, deferoxamine mesylate, 500 mg |
| J3520 | HCPCS | Edetate disodium, per 150 mg |
| M0300 | HCPCS | IV chelation therapy (chemical endarterectomy) |
| S9355 | HCPCS | Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment |
Key ICD-10-CM Diagnosis Codes
The full policy includes 824 ICD-10-CM codes. Below are the highest-volume and highest-specificity codes relevant to chelation therapy billing.
| Code | Description |
|---|---|
| D56.0–D56.9 | Thalassemia (including Cooley's anemia/thalassemia major) |
| D57.00–D57.819 | Sickle-cell disorders (excludes sickle-cell ulcers) |
| D61.01 | Constitutional (pure) red blood cell aplasia — Blackfan-Diamond syndrome |
| D46.22 | Refractory anemia with excess of blasts 2 |
| D46.9 | Myelodysplastic syndrome, unspecified |
| D46.C | Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality |
| D46.Z | Other myelodysplastic syndromes |
| D50.0–D50.9 | Iron deficiency anemia |
| E72.01 | Cystinuria |
| E83.01 | Wilson's disease |
| E61.3 | Manganese deficiency |
| E08.00–E13.9 | Diabetes mellitus (listed for cardiovascular event prevention context — chelation NOT covered for this indication) |
| A69.20–A69.29 | Lyme disease (listed in ICD-10 table — verify specific indication coverage before billing) |
| B46.0–B46.9 | Zygomycosis (listed in ICD-10 table — verify specific indication coverage before billing) |
| C00.0–C96.9 | Malignant neoplasm |
| D00.00–D09.9 | Carcinoma in situ |
For the complete list of 824 ICD-10-CM codes under this policy, access the full policy document at the Aetna CPB 0234 source.
Get the Full Picture for CPT 83015
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.